90 assets in Ovarian Serous Adenocarcinoma

Therapeutic assets addressing Ovarian Serous Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Ovarian Serous Adenocarcinoma	National Cancer Institute (NCI)	P3	BBB (72)
Adriamycin Ovarian Serous Adenocarcinoma	National Cancer Institute (NCI)	P3	BB (70)
Cyclophosphamide Ovarian Serous Adenocarcinoma	Roswell Park Cancer Institute	P2	BB (70)
Letrozole Ovarian Serous Adenocarcinoma	Memorial Sloan Kettering Cancer Center	P3	BB (70)
Olaparib Ovarian Serous Adenocarcinoma	Institute of Cancer Research, United Kingdom	P3	BB (70)
Avutometinib Ovarian Serous Adenocarcinoma	Verastem, Inc.	P3	BB (68)
Cediranib Ovarian Serous Adenocarcinoma	National Cancer Institute (NCI)	P2/3	BB (68)
Cis-Diamminedichloroplatinum Ii Ovarian Serous Adenocarcinoma	Genelux Corporation	P3	BB (68)
Defactinib Ovarian Serous Adenocarcinoma	Verastem, Inc.	P3	BB (68)
Nogitecan Ovarian Serous Adenocarcinoma	National Cancer Institute (NCI)	P3	BB (68)
Pembrolizumab Ovarian Serous Adenocarcinoma	Roswell Park Cancer Institute	P2	BB (67)
Docetaxel Ovarian Serous Adenocarcinoma	Genelux Corporation	P3	BB (65)
Nivolumab Ovarian Serous Adenocarcinoma	pharmaand GmbH	P2	B (63)
Abemaciclib Ovarian Serous Adenocarcinoma	AstraZeneca	P2	B (62)
Binimetinib Ovarian Serous Adenocarcinoma	National Cancer Institute (NCI)	P3	B (62)
Anastrozole Ovarian Serous Adenocarcinoma	Verastem, Inc.	P3	B (60)
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine Ovarian Serous Adenocarcinoma	Mayo Clinic	P2	B (60)
Olvimulogene Nanivacirepvec Ovarian Serous Adenocarcinoma	Genelux Corporation	P3	B (60)
Niraparib Ovarian Serous Adenocarcinoma	Sunnybrook Health Sciences Centre	P2	B (59)
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter Ovarian Serous Adenocarcinoma	Mayo Clinic	P2	B (59)
Palbociclib Ovarian Serous Adenocarcinoma	National Cancer Institute (NCI)	P2	B (58)
Atezolizumab Ovarian Serous Adenocarcinoma	National Cancer Institute (NCI)	P2/3	B (57)
Durvalumab Ovarian Serous Adenocarcinoma	National Cancer Institute (NCI)	P2	B (57)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Ovarian Serous Adenocarcinoma	National Cancer Institute (NCI)	P2	B (57)
mk-4830 Ovarian Serous Adenocarcinoma	Merck Sharp & Dohme LLC	P2	B (57)
Upifitamab Rilsodotin Ovarian Serous Adenocarcinoma	Mersana Therapeutics	P3	B (57)
Oregovamab Ovarian Serous Adenocarcinoma	CanariaBio Inc.	P3	B (56)
Ipilimumab Ovarian Serous Adenocarcinoma	TCR2 Therapeutics	P1/2	CCC (55)
Adsorbed Purified Pertussis Vaccine Ovarian Serous Adenocarcinoma	Mayo Clinic	P2	CCC (53)
Aitua Combination Antibody Ovarian Serous Adenocarcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Anetumab Ravtansine Ovarian Serous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Atovaquone Ovarian Serous Adenocarcinoma	Emory University	P2	CCC (53)
Copanlisib Ovarian Serous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Diphtheria Toxoid Ovarian Serous Adenocarcinoma	Mayo Clinic	P2	CCC (53)
Diphtheria Toxoid Adsorbed Ovarian Serous Adenocarcinoma	Mayo Clinic	P2	CCC (53)
Fluzoparib Ovarian Serous Adenocarcinoma	Guangxi Medical University	P2	CCC (53)
Fulvestrant Ovarian Serous Adenocarcinoma	University of Oklahoma	P2	CCC (53)
Gotistobart Ovarian Serous Adenocarcinoma	OncoC4, Inc.	P2	CCC (53)
Ici-Hipet Ovarian Serous Adenocarcinoma	Jing Li	P2	CCC (53)
Lenvatinib Ovarian Serous Adenocarcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Nab-Sirolimus Ovarian Serous Adenocarcinoma	University of Oklahoma	P2	CCC (53)
Pegcetacoplan Ovarian Serous Adenocarcinoma	Roswell Park Cancer Institute	P2	CCC (53)
Regorafenib Ovarian Serous Adenocarcinoma	Sarah K. Lynam MD	P2	CCC (53)
Rivoceranib Ovarian Serous Adenocarcinoma	Guangxi Medical University	P2	CCC (53)
Tetanus Toxoid Ovarian Serous Adenocarcinoma	Mayo Clinic	P2	CCC (53)
Cdx 1140 Ovarian Serous Adenocarcinoma	Roswell Park Cancer Institute	P2	CCC (51)
Ibentatug Ovarian Serous Adenocarcinoma	ZielBio, Inc.	P1/2	CCC (50)
Deoxycholic Acid Ovarian Serous Adenocarcinoma	THERAPIM PTY LTD	P1/2	CCC (48)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Ovarian Serous Adenocarcinoma	Regeneron Pharmaceuticals	P1/2	CCC (48)
Sarilumab Ovarian Serous Adenocarcinoma	Regeneron Pharmaceuticals	P1/2	CCC (48)

Showing 1 to 50 of 90 assets

PreviousPage 1 of 2Next